Management of drug resistance in the population: Influenza as a case study

Proceedings of the Royal Society B: Biological Sciences

Volumn 275, Issue 1639, 2008, Pages 1163-1169

  Moghadas, Seyed M ^a,b  

^a UNIVERSITY OF WINNIPEG   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Drug resistance; Epidemic models; Pathogen evolution; Treatment

Indexed keywords

DISEASE TREATMENT; DRUG RESISTANCE; EVOLUTION; IMMUNE RESPONSE; IMMUNITY; INFLUENZA; MODELING; MUTATION; NUMERICAL MODEL;

ANTIVIRAL RESISTANCE; ARTICLE; EVOLUTION; GENE MUTATION; HOST PATHOGEN INTERACTION; HOST SUSCEPTIBILITY; IMMUNE RESPONSE; INFLUENZA; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; THERAPY RESISTANCE; VIRUS STRAIN;

EID: 41649104101     PISSN: 09628452     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rspb.2008.0016     Document Type: Article

References (41)

1. Alexander, M. E., Bowman, C. S., Feng, Z., Gardam, M., Moghadas, S. M., Röst, G., Wu, J. & Yan, P. 2007 Emergence of drug-resistance: implications for antiviral control of pandemic influenza. Proc. R. Soc. B 274, 1675-1684. (doi:10.1098/rspb.2007.0422)
2. Alexander, M. E., Moghadas, S. M., Röst, G. & Wu, J. 2008 A delay differential model for pandemic influenza with antiviral treatment. Bull. Math. Biol. 70, 382-397. (doi:10.1007/s11538-007-9257-2)
3. Anderson, R. M. 2006 Planning for pandemics of infectious diseases. Bridge 36, 5-9.
4. Anderson, R. M. & May, R. M. 1992 Infectious diseases of humans. Oxford, UK: Oxford University Press.
5. Andreasen, V., Lin, J. & Levin, S. A. 1997 The dynamics of cocirculating influenza strains conferring partial cross-immunity. J. Math. Biol. 35, 825-842. (doi:10.1007/s002850050079)
6. Aoki, F. Y. et al. 2003 Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51, 123-129. (doi:10.1093/jac/dkg007)
7. Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G. & Perelson, A. S. 2006 Kinetics of influenza A virus infection in humans. J. Virol. 80, 7590-7599. (doi:10.1128/JVI.01623-05)
8. Blower, S. & Chou, T. 2004 Modeling the emergence of the 'host zones': tuberculosis and the amplification dynamics of drug-resistance. Nat. Med. 10, 1111-1116. (doi:10.1038/nm1102)
9. Blower, S., Ma, L., Farmer, P. & Koenig, S. 2003 Predicting the impact of antiretrovirals in resourse-poor settings: preventing HIV infection whilst controlling drug resistance. Curr. Drugs Targets Infect. Disord. 3, 345-353. (doi:10.2174/1568005033480999)
10. Blower, S., Bodine, E., Khan, J. & McFarland, W. 2004 The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 19, 1-14.
11. Bonhoeffer, S., Lipsitch, M. & Levin, B. R. 1997 Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl Acad. Sci. USA 94, 12 106-12 111. (doi:10.1073/pnas.94.22.12106)
12. Boni, M. F., Gog, J. R., Andreasen, V. & Feldman, M. W. 2006 Epidemic dynamics and antigenic evolution in a single season of influenza A. Proc. R. Soc. B 273, 1307-1316. (doi:10.1098/rspb.2006.3466)
13. Bright, R. A., Medina, M. J., Xu, X., Perez-Oronoz, G., Wallis, T. R., Davis, X. M., Povinelli, L., Cox, N. J. & Klimov, A. I. 2005 Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366, 1175-1181. (doi:10.1016/S0140-6736(05)67338-2)
14. Coffin, J. M. 1995 HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489. (doi:10.1126/science.7824947)
15. Coffin, J. M. 1996 HIV viral dynamics. AIDS 10(Suppl. 3), S75-S84.
16. Débarre, F., Bonhoeffer, S. & Regoes, R. R. 2007 The effect of population structure on the emergence of drug-resistance during pandemic influenza. J. R. Soc. Interface 4, 893-906. (doi:10.1098/rsif. 2007.1126)
17. de Jong, M. D. et al. 2005 Oseltamivir resistance during treatment of influenza A (H5N1) infection. NEJM 353, 2667-2672. (doi:10.1056/NEJMoa054512)
18. Diekmann, O. & Heesterbeek, J. A. P. 2000 Mathematical epidemiology of infectious diseases. Chichester, UK: Wiley.
19. Ferguson, N. M., Mallett, S., Jackson, H., Roberts, N. & Ward, P. 2003 A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J. Antimicrob. Chemother. 51, 977-990. (doi:10.1093/jac/dkg136)
20. Ferguson, N. M., Cummings, D. A. T., Cauchemez, S., Fraser, C., Riley, S., Meeyai, A., Iamsirithaworn, S. & Burke, D. S. 2005 Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437, 209-214. (doi:10.1038/nature04017)
21. Gani, R., Hughes, H., Fleming, D., Griffin, T., Medlock, J. & Leach, S. 2005 Potential impact of antiviral drug use during influenza pandemic. Emerg. Infect. Dis. 9, 1355-1362.
22. Halloran, M. E., Hayden, F. G., Yang, Y., Longini Jr, I. M. & Monto, A. S. 2006 Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am. J. Epidemiol. 165, 212-221. (doi:10.1093/aje/kwj362)
23. Handel, A., Regoes, R. R. & Antia, R. 2006 The role of compensatory mutations in the emergence of drug resistance. PLoS 2, 1262-1270. (doi:10.1371/journal.pcbi.0020137)
24. Handel, A., Longini Jr, I. M. & Antia, R. 2007 Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput. Biol. 3, e240. (doi:10.1371/journal.pcbi. 0030240)
25. Jennings, L. C. & Peiris, M. 2006 Avian influenza H5N1: is it a cause for concern? Intern. Med. J. 36, 145-147. (doi:10.1111/j.1445- 5994.2006.01036.x)
26. Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N. & Kawaoka, Y. 2004 Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364, 759-765. (doi:10.1016/S0140-6736(04)16934-1)
27. Kuiken, T., Holmes, E. C., McCauley, J., Rimmelzwaan, G. F., Williams, C. S. & Grenfell, B. T. 2006 Host species barriers to influenza virus infections. Science 312, 394-397. (doi:10.1126/science.1122818)
28. Lloyd, A. L. & Wodarz, D. 2006 Drug-resistance in acute viral infections: rhinovirus as a case study. In Disease evolution: models, concepts, and data analyses. DIMACS series in discrete mathematics and theoretical computer science, pp. 193-212. Providence, RI: AMS.
29. Longini Jr, I. M., Nizam, A., Xu, S., Ungchusak, K., Hanshaoworakul, W., Cummings, D. A. T. & Halloran, M. E. 2005 Containing pandemic influenza at the source. Science 309, 1083-1087. (doi:10.1126/science.1115717)
30. Moscona, A. 2005 Oseltamivir resistance - disabling our influenza defenses. N. Engl. J. Med. 353, 2633-2636. (doi:10.1056/ NEJMp058291)
31. Nelson, K. E., Williams, C. M. & Graham, N. M. H. 2004 Infectious disease epidemiology, theory and practice. Sudbury, MA: Jones and Bartlett Publishers.
32. Newman, M. E. J. 2005 Threshold effects for two pathogens spreading on a network. Phys. Rev. Lett. 95, 108 701. (doi:10.1103/PhysRevLett. 95.108701)
33. Regoes, R. R. & Bonhoeffer, S. 2006 Emergence of drug-resistance influenza virus: population dynamical considerations. Science 312, 389-391. (doi:10.1126/science.1122947)
34. Richman, D. D. 1994 Drug resistance in viruses. Trends Microbiol. 2, 401-407. (doi:10.1016/0966-842X(94)90619-X)
35. Richman, D. D. 1996 Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Adv. Exp. Med. Biol. 394, 383-395.
36. Rimmelzwaan, G. F., Berkhoff, E. G. M., Nieuwkoop, N. J., Smith, D. J., Fouchier, R. A. M. & Osterhaus, A. D. M. E. 2005 Full restoration of viral fitness by multiple compensatory co-mutations in the nucleoprotein of influenza A virus cytotoxic T-lymphocyte escape mutants. J. Gen. Virol. 86, 1801-1805. (doi:10.1099/vir.0.80867-0)
37. Stilianakis, N. I., Perelson, A. S. & Hayden, F. G. 1998 Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J. Infect. Dis. 177, 863-873.
38. Swain, S. L., Dutton, R. W. & Woodland, D. L. 2004 T cell responses to influenza virus infection: effector and memory cells. Viral. Immunol. 17, 197-209. (doi:10.1089/0882824041310577)
39. Wodarz, D. 2001 Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance. J. Theor. Biol. 213, 447-459. (doi:10.1006/jtbi.2001.2426)
40. Wodarz, D. & Lloyd, A. L. 2004 Immune responses and the emergence of drug-resistant virus strains in vivo. Proc. R. Soc. B 271, 1101-1109. (doi:10.1098/rspb.2003.2664)
41. Yen, H. L., Herlocher, L. M., Hoffmann, E., Matrosovich, M. N., Monto, A. S., Webster, R. G. & Govorkova, E. A. 2005 Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49, 4075-4084. (doi:10.1128/AAC.49.10.4075-4084.2005)